AEON.US AEON Biopharma, Inc.

Healthcare Biotechnology USA Stocks
0.1678 USD
Close of Nov 13, 2026
0.1270 1.45
Market cap
USD 12.0M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is AEON.US undervalued?

Graham number

The Graham number of AEON Biopharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AEON Biopharma, Inc. fundamental analysis

No fundamental analysis for AEON Biopharma, Inc. yet.

AEON Biopharma, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AEON Biopharma, Inc.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements …

Full company profile